PATH Study: Patient Navigation for Pregnant Women
This study, called PATH (Partnering with Antenatal Navigators to Transform Health in Pregnancy), is testing a program where you would work with an antenatal patient navigator. This program aims to help reduce barriers to care, improve your access to healthcare, and enhance your knowledge about pregnancy. The study wants to see if this program can improve the health of both mothers and babies, as well as pregnant women's experiences with healthcare. You might be able to join if you are a woman between 16 and 50 years old, less than 20 weeks pregnant with one baby, have never had a pregnancy last 20 weeks or more (excluding terminations), have a low income, and can speak and read English or Spanish. The study will measure success by looking at maternal (mother's) and neonatal (newborn's) adverse outcomes. The current recruitment status is unclear.
- Study design
- This is an interventional study that plans to enroll 600 participants. It is a randomized controlled trial, meaning participants will be randomly assigned to either receive the patient navigation program or usual care.
- What's involved
- Navigators will support pregnant women from before 20 weeks of gestation through 2 weeks postpartum. The study will measure maternal outcomes from enrollment through delivery hospitalization (an average of 28 weeks) and neonatal outcomes at birth/delivery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Maternal adverse outcomes are measured through delivery hospitalization (an average of 28 weeks). Neonatal adverse outcomes are measured at birth/delivery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Partnering With Antenatal Navigators to Transform Health in Pregnancy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Lynn M Yee, MD, MPH · PRINCIPAL_INVESTIGATOR · Northwestern University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Maternal adverse outcome composite (Aim 1 primary outcome)Enrollment through delivery hospitalization, an average of 28 weeks
Frequency of maternal composite, which includes hypertensive disorders of pregnancy, preterm birth, postpartum hemorrhage, severe maternal morbidity, or maternal mortality. Components of the primary outcome will also be examined as a score and individually as secondary outcomes (see below).
- Neonatal adverse outcome composite (Aim 2 primary outcome)At birth/delivery
Frequency of the neonatal composite, which includes neonatal intensive care unit (NICU) admission, low birthweight, small-for-gestational-age (SGA), large-for-gestational-age (LGA) status, and/or perinatal death. Components of the composite outcome will also be examined as a score and individually as secondary outcomes (see below).